Tymlos (abaloparatide) and Forteo (teriparatide) are the two daily bone-building injections approved for osteoporosis in the US. They are both 34-amino-acid peptides acting on the same parathyroid hormone receptor, and they are usually discussed as alternatives. What each one is, in its own entry, is in Peptide Lexicon's abaloparatide and teriparatide pages. Their side effects have their own pages here: Tymlos side effects and Forteo side effects. This page compares the rest: what each was shown to do, who each is approved for, and how the products differ in use. It reports the labels and trials and recommends neither.
The one trial that gave both
ACTIVE (NCT01343004; Miller et al., JAMA 2016) randomised 2,463 postmenopausal women with osteoporosis to 18 months of daily placebo, abaloparatide 80 mcg or teriparatide 20 mcg. These are its posted results, read from ClinicalTrials.gov on 10 November 2026.
| Outcome at 18 months | Placebo | Abaloparatide (Tymlos) | Teriparatide (Forteo), open-label |
|---|---|---|---|
| New vertebral fracture | 30 of 711 (4.22%) | 4 of 690 (0.58%) | 6 of 717 (0.84%) |
| Non-vertebral fracture | 33 of 821 (4.02%) | 18 of 824 (2.18%) | 24 of 818 (2.93%) |
| Lumbar-spine bone density, mean change | +0.48% | +9.20% | +9.12% |
| Total-hip bone density, mean change | −0.08% | +3.44% | +2.81% |
| Femoral-neck bone density, mean change | −0.44% | +2.90% | +2.26% |
| Hypercalcaemia-related adverse events (events, not patients) | 5 | 15 | 34 |
How to read it, in four points.
- Both drugs cut fractures sharply against placebo. That is the finding the trial was built to test, for abaloparatide, and it is the basis of the fracture claim on the Tymlos label (0.6% against 4.2% for vertebral fractures).
- Between the two drugs, the trial cannot settle it. The sample size was set to detect a 4-point difference against placebo. The gap between the two active arms is 2 vertebral fractures in roughly 700 women each, and ACTIVE's own conclusion calls for further research on how abaloparatide compares with other treatments.
- The bone-density pattern is the clearest difference. At the spine, the two arms rose by almost the same amount (9.20% against 9.12%). At the hip and femoral neck, abaloparatide's mean rise was larger by about 0.6 percentage points.
- The teriparatide arm was open-label. Placebo and abaloparatide were blinded; teriparatide was not. Reported events in that arm, including hypercalcaemia, may not be measured on the same footing. In the published paper, 3.4% of women on abaloparatide and 6.4% on teriparatide had hypercalcaemia, the safety end point the trial set for the two drugs.
The Forteo label's own fracture evidence comes from an earlier placebo-controlled trial of 1,637 women, in which new vertebral fractures fell from 14.3% on placebo to 5.0% on teriparatide. That trial's women were at higher risk — 90% already had a vertebral fracture — so its rates are not comparable with ACTIVE's.
What each label covers
| Tymlos (abaloparatide) | Forteo (teriparatide) | |
|---|---|---|
| Postmenopausal women at high risk of fracture | Yes — reduces vertebral and non-vertebral fractures | Yes — reduces vertebral and non-vertebral fractures |
| Men | Yes — to increase bone density (12-month trial of 228 men) | Yes — to increase bone mass in primary or hypogonadal osteoporosis (trial of 437 men) |
| Glucocorticoid-induced osteoporosis | Not on the label | Yes — men and women on 5 mg a day or more of prednisone or equivalent |
| Duration wording | More than 2 years in a lifetime "is not recommended" | More than 2 years "should only be considered" if fracture risk stays or returns to high |
| Label read | Radius Health, DailyMed listing 17 August 2026 | Eli Lilly, DailyMed listing 19 August 2026 |
The men's trials measured bone density, not fractures, which is why both labels word the men's indication as increasing bone density or bone mass. In Tymlos's 12-month men's trial, lumbar-spine density rose 8.5% against 1.2% on placebo. In Forteo's men's trial, with a median of 10 months on treatment, it rose 5.9% against 0.5%. The trials differ in length and population, so the two figures are not a ranking.
How the products differ in use
| Tymlos | Forteo | |
|---|---|---|
| Labelled dose | 80 mcg under the skin once daily | 20 mcg under the skin once daily |
| Injection site on the label | Around the navel (periumbilical abdomen) | Thigh or abdomen |
| Pen | 30 doses | 28 doses; discard 28 days after first use |
| Storage | Refrigerated before first use; up to 30 days at room temperature after first use | Refrigerated at all times except when injecting |
| Generics and other brands | None listed on DailyMed | Bonsity and several generic teriparatide products listed |
Storage is the practical difference most often raised: the Tymlos pen does not need a refrigerator once it is in use, and the Forteo pen does. For how pen devices work across the peptide class, see peptide pens. For the dosing arithmetic of teriparatide as the label sets it out, see teriparatide dosage.
What is not established
- Whether one drug prevents more fractures than the other. No trial was designed and powered to answer it.
- Long-term comparative outcomes. ACTIVE ran 18 months on drug; its extension switched both groups to alendronate, and the teriparatide arm did not continue into it.
- Fracture outcomes in men for either drug. Both men's trials measured bone density only.
- Cost comparisons. Prices change, so they are kept on a separate, dated page: what a Tymlos or Forteo pen costs in public price data, per pen, per month and over the two-year course.
Who makes the decision
Which drug, for how long and what follows it are decisions for the prescribing clinician. This page reports the labels and the trial results and does not replace them.
Sources and dates
- ClinicalTrials.gov API v2, NCT01343004 (ACTIVE), posted outcome measures — read 10 November 2026.
- Miller PD et al. JAMA 2016;316(7):722–33. PMID 27533157.
- Tymlos (abaloparatide) injection, Radius Health, US prescribing information, DailyMed, listed 17 August 2026 (revised 08/2026) — sections 1, 2, 14 and 16. Read 10 November 2026.
- Forteo (teriparatide) injection, Eli Lilly, US prescribing information, DailyMed, listed 19 August 2026 (revised 08/2026) — sections 1, 2, 14 and 16. Read 10 November 2026.
- DailyMed teriparatide and abaloparatide listings, read 10 November 2026.
